Episode Details

Back to Episodes
Pharmaceutical Executive Daily: FDA Approves Simtriyo

Pharmaceutical Executive Daily: FDA Approves Simtriyo

Published 3 months, 3 weeks ago
Description
In today's Pharmaceutical Executive Daily, FDA approves Otsuka's Simtriyo as the first NDSRI treatment for ADHD, argenx agrees to acquire Forte Biosciences for approximately $2.2 billion, and an AbbVie neuroscience researcher discusses the shift from symptom management to disease modification in Parkinson's research.
Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us